Stoke Therapeutics (STOK) Competitors

Stoke Therapeutics (NASDAQ:STOK) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

Is STOK or KYMR more profitable?

Stoke Therapeutics has a net margin of 26.25% compared to Kymera Therapeutics' net margin of -616.03%. Stoke Therapeutics' return on equity of 19.41% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stoke Therapeutics	26.25%	19.41%	16.20%
Kymera Therapeutics	-616.03%	-31.60%	-27.12%

Do analysts recommend STOK or KYMR?

Stoke Therapeutics presently has a consensus target price of $25.17, suggesting a potential upside of 46.57%. Kymera Therapeutics has a consensus target price of $59.11, suggesting a potential upside of 42.27%. Given Stoke Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Stoke Therapeutics is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stoke Therapeutics	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.25
Kymera Therapeutics	0 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	3.10

Does the media prefer STOK or KYMR?

In the previous week, Kymera Therapeutics had 1 more articles in the media than Stoke Therapeutics. MarketBeat recorded 18 mentions for Kymera Therapeutics and 17 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 0.49 beat Kymera Therapeutics' score of 0.38 indicating that Stoke Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stoke Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kymera Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Which has more volatility and risk, STOK or KYMR?

Stoke Therapeutics has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 2.18, indicating that its share price is 118% more volatile than the S&P 500.

Which has preferable valuation and earnings, STOK or KYMR?

Stoke Therapeutics has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stoke Therapeutics	$36.56M	25.64	-$88.98M	$0.79	21.73
Kymera Therapeutics	$47.07M	63.12	-$223.86M	-$3.47	-11.97

Summary

Stoke Therapeutics beats Kymera Therapeutics on 9 of the 15 factors compared between the two stocks.